



Selective determination of ubiquinone in human plasma by HPLC with 
chemiluminescence reaction based on the redox cycle of quinone  
 
Naoya Kishikawa*, Nobuhiro Ohkubo, Kaname Ohyama, Kenichiro Nakashima, 
Naotaka Kuroda 
 
N. Kishikawa, N. Ohkubo, K. Ohyama, K. Nakashima, N. Kuroda 
Graduate School of Biomedical Sciences, Course of Pharmaceutical Sciences, Nagasaki 












Ubiquinone is an important biologically active compound in living body.  The 
determination of ubiquinone in human plasma is useful for the investigation of 
bioavailability of ubiquinone and for early diagnosis of several diseases.  Therefore, 
we developed an HPLC-chemiluminescence detection method for the analysis of 
ubiquinone in plasma samples.  The method is based on luminol chemiluminescence 
detection of super oxide anion that generated by the redox cycle reaction between 
ubiquinone and dithiothreitol. The HPLC system involved an octyl column with a 
mobile phase of methanol.  Ubiquinone eluted from the column was mixed with 
dithiothreitol and luminol solutions simultaneously and generated chemiluminescence 
was monitored by chemiluminescence detector.  The calibration curve for standard 
ubiquinone solution was linear from 0.09 to 43.2 µg/mL (0.22-216 ng on column) with 
the correlation coefficient of 0.999, and the detection limit (S/N = 3) was 26 ng/mL 
(130 pg on column).  Using the proposed HPLC method, the peak of ubiquinone in 
human plasma could be clearly detected on the chromatogram without any interferences 
from plasma components.  
  





Ubiquinone (also called coenzyme Q10) is an important biologically active 
compound which has several roles in the living body.  For example, ubiquinone is an 
electron carrier in the mitochondrial electron transport chain and participates in aerobic 
cellular respiration and generating energy [1].  Besides, ubiquinone has antioxidant 
activity and protects circulating lipoproteins against oxidative damage, therefore the 
ubiquinone concentration in blood may reflect the redox status in human body [1,2].      
Furthermore, it has been reported that the plasma levels of ubiquinone in patients with 
certain diseases including hyperthyroidism, melanoma, cystic fibrosis and 
phenylketonuria and mevalonic aciduria are significantly lower than those in healthy 
subjects [3-6].  Therefore, the determination of ubiquinone can be useful for diagnosis 
of these diseases.  In addition, since ubiquinone is used as a therapeutic agent for heart 
diseases, monitoring of ubiquinone in human plasma is important to investigate its 
bioavailability and pharmacokinetic properties [7].  Considering these aspects, a 
sensitive and selective analytical method for ubiquinone is required in various 
situations. 
Several analytical methods have been developed for the determination of 
ubiquinone in blood samples using high-performance liquid chromatography (HPLC) 




tandem mass spectrometry (MS/MS) [12].  However, HPLC-UV methods lack 
sensitivity and suffer from interferences due to co-existing substances.  HPLC-ECD 
methods require a complicated system because ubiquinone should be converted to 
ubiquinol by chemical catalytic reduction with reducer column or electroreduction 
reaction with in-line electrode just before the detector.  In spite of the high sensitivity 
and selectivity of HPLC-MS/MS method, the high cost of the mass spectrometer limits 
the widespread use.  Among detection techniques, it is known that chemiluminescence 
(CL) detection provides high sensitivity with simple equipment.  Therefore, HPLC 
with CL detection has been widely applied to the determination of biologically active 
compounds in blood samples [13,14].  However, until now, a method for the 
determination of ubiquinone in blood using CL detection has not been developed. 
 Recently, we have reported a novel CL assay for quinones including 
ubiquinone based on the their redox reaction cycle [15].  In this batch method, 
quinones were reduced to semiquinone radicals by dithiothreitol (DTT) as a reductant.  
Successively, semiquinone radicals convert dissolved oxygen to superoxide anion, 
which reacts with luminol to generate CL (Fig. 1).  When the CL assay was used to 
determine the content of ubiquinone in pharmaceutical formulations, it was found that 
the assay was specific for ubiquinone even in the presence of pharmaceutical additives.  




system for the determination of ubiquinone in biological samples.   Finally, we 
successfully applied the developed HPLC method to determine ubiquinone in human 







Ubiquinone was purchased from Kanto Chemical (Tokyo, Japan).  DTT, 
ethanol and methanol were obtained from Nacalai Tesque (Kyoto, Japan).  Luminol 
was purchased from Sigma (St. Louis, MO, USA) and sodium hydroxide (NaOH) was 
from Merck (Tokyo, Japan).    Purified water was prepared by a Simpli Lab UV 
(Millipore, Bedford, MA, USA) water device.  2-Henicosyl-1,4-naphthoquinone as an 
internal standard (IS) was synthesized from 1,4-naphthoquinone and behenic acid in our 
laboratory according to the previously reported method [16].  Other chemicals were of 
extra pure grade.  Stock solutions of ubiquinone were prepared in ethanol and diluted 
with ethanol to prepare the working solutions.  Solutions of DTT and luminol were 
prepared in methanol and NaOH aqueous solution, respectively, just before analysis. 
 
2.2. Instrument 
The HPLC system (Fig. 2) consisted of three LC-10AS liquid chromatographic 
pumps (Shimadzu, Kyoto), a Rheodyne 7125 injector (Cotati, CA, USA) with a 5-µL 
sample loop, a CLD-10A chemiluminescence detector (Shimadzu), a UNI-1 noise filter 




(15 m x 0.5 mm i.d., GL Sciences, Tokyo) was used as reaction coil.  A Cosmosil 
5C8-MS (150 mm x 4.6 mm, i.d., 5 µm, Nacalai Tesque) and methanol was used as 
stationary and mobile phase, respectively.  The eluent from the column was mixed 
with 1.5 mM of DTT in methanol and 1.0 mM of luminol in 150 mM NaOH aqueous 
solution, simultaneously.  The flow rates of the mobile phase, DTT and luminol 
solution were set at 0.50, 0.30 and 0.25 mL/min, respectively.  For the comparison 
study, a UV-8010 UV detector (TOSOH, Tokyo) was used at a wavelength of 275 nm. 
 
2.3. Assay procedure for ubiquinone in human plasma 
Fifty micro liters of plasma were spiked with 10 µL of 2.26 µg/mL IS 
(2-henicosyl-1,4-naphthoquinone) solution, and then 10 µL of 0.3% hydrogen peroxide 
was added to oxidize ubiquinol to ubiquinone.  One-hundred micro liter of ethanol was 
added to denature protein and then vortexed for 1 min.  To this solution, 600 µL of 
n-hexane was added to extract ubiquinone and IS.  The organic layer was taken and 
evaporated under reduced pressure, and the residue was reconstituted with 50 µL of 
methanol and then 5 µL was injected into the HPLC system.  The present experiments 
were approved by the Ethics Committee of the School of Pharmaceutical Sciences, 





3. Results and discussion 
 
3.1. Optimization of HPLC conditions 
Considering the high lipophilic nature of ubiquinone, an octyl column and 
methanol were selected as stationary and mobile phase, respectively.  Ubiquinone 
eluted from the column was mixed with DTT and luminol solutions in the reaction coil 
and the generated CL was monitored.  Figure 3A shows a typical chromatogram 
obtained by the proposed HPLC system.  The peaks of ubiquinone and IS were 
detected at 15 and 30 min, respectively. The effects of the conditions of the proposed 
HPLC-CL system on peak height and S/N ratio of ubiquinone were investigated to 
obtain the highest sensitivity.  In our previous study [15], it was observed that the CL 
intensity of ubiquinone after mixing with DTT and luminol increased slowly.  
Therefore, the mixed solution was introduced to CL detector after passing through a 
PTFE tube as a reaction coil in order to obtain suitable CL at the detector.  The effects 
of coil length ranging from 9 to 18 m on peak height and S/N ratio were examined (Fig. 
4).  The peak height increased with the increase of coil length until 16 m and then 
decreased.  Although the maximum peak height was achieved at 16 m, the reaction 




coil length corresponds to the reaction time of 100 s.  The reagent concentrations were 
also optimized.  The effects of DTT concentration on peak height and S/N ratio were 
examined.  Since the peak height and S/N ratio increased with the increase of DTT 
concentration till 1.5 mM, 1.5 mM was selected.  Also, the influence of luminol 
concentration was examined  (Fig. 5).  It was found that the peak height increased 
with the increase in luminol concentration;  1.0 mM of luminol, which gave the 
maximum S/N ratio, was selected.  The effects of concentration of NaOH solution for 
dissolving luminol on peak height and S/N ratio were examined.  The peak height 
reached the maximum when NaOH concentration was more than 140 mM, and the 150 
mM of NaOH gave the best S/N ratio. 
 
3.2. Calibration curve and detection limit 
A calibration curve for standard ubiquinone was constructed by plotting the peak 
height ratio to IS against the concentration of ubiquinone.  The calibration curve of the 
proposed HPLC method was linear from 0.09 to 43.2 µg/mL (0.22-216 ng on column) 
with the correlation coefficient of 0.999, and the detection limit (S/N = 3) was 26 ng/mL 
(130 pg on column).  The regression equation (mean ± standard error, n = 3) was 2.23 




approximately 60 times and 10 times higher than those of HPLC-UV [8] and HPLC 
with post-column colorimetric reaction method [9], respectively.  Additionally, the 
sensitivity was almost comparable to those of HPLC-ECD with catalytic reduction [10], 
HPLC-ECD with electroreduction [11], HPLC-MS/MS [12] and ultra-performance 
liquid chromatography with mass spectrometry (UPLC-MS) [17] in spite of the 
complexity of the proposed detection system was lower compared to those of these 
methods. 
 
3.3. Determination of UQ in human plasma 
The developed HPLC-CL system was applied to determine the concentration of 
ubiquinone in human plasma.  The preparation procedure for human plasma was 
modified according to the previous report [10].  Since it has been reported that the 
most of ubiquinone molecules are presented as reduced form (ubiquinol) in human 
plasma [18], oxidation by hydrogen peroxide was employed for the conversion of 
ubiquinol to ubiquinone prior to the extraction.  A typical chromatogram of plasma 
extract from healthy subject by the proposed HPLC-CL method is shown in Fig. 3B.  
The peaks of ubiquinone and IS in plasma could be clearly detected on the 
chromatogram without interferences from other plasma components.  To demonstrate 




injected to HPLC-UV system using the same separation conditions as the HPLC-CL 
system.  Figure 3C shows a chromatogram of plasma extract obtained by UV detection.  
In contrast with the result obtained by CL methods, several large peaks were observed 
and the determination of ubiquinone was difficult due to extremely weak peak response 
of ubiquinone.  The calibration curve for recovered ubiquinone from human plasma 
was linear over the range from 0.09 to 8.63 µg/mL with a correlation coefficient of 
0.999.  The recovery and reproducibility of the proposed method were evaluated by the 
analysis of the plasma samples spiked with a known amount of ubiquinone.  As shown 
in Table 1, the RSDs for within-day and between-day reproducibility ranged from 0.8 to 
4.5% and from 2.7 to 3.9%, respectively, and the excellent recoveries were achieved 
more than 98.2%.   The stability of ubiquinone in plasma samples was evaluated by 
comparing the results of stored samples under different conditions with freshly prepared 
samples.  The short- and long-term stabilities were evaluated during storage at room 
temperature for 4 h and at −80 °C for 2 weeks, respectively.  The freeze–thaw stability 
was evaluated after three freeze–thaw cycles from −80 °C to room temperature.   As 
shown in Table 2, the results suggested the sufficient stability of ubiquinone during the 
storage period at room temperature for 4 h, at −80 ºC for 2 weeks and after three 
freeze-thaw cycles.  In addition, the matrix effects were evaluated by comparing the 




plasma samples spiked with ubiquinone at three concentration levels.  The matrix 
effects (mean ± SD, n = 3) for ubiquinone at concentrations of 0.43, 1.73 and 8.63 
ng/mL were 95.6 ± 4.0%, 99.8 ± 5.3% and 95.3 ± 1.8%, respectively.  The results 
revealed that there were no significant matrix effects from plasma extracts.  Therefore, 
the proposed method allows highly accurate determination of ubiquinone in human 
plasma.  The determined value of ubiquinone in human plasma (0.46 ± 0.18 µg/mL, n 






The present study is the first attempt to measure ubiquinone concentration in 
biological fluids using CL detection.  We developed a new HPLC method for the 
analysis of ubiquinone based on the CL generated during the reaction of ubiquinone 
with DTT and luminol.    The sensitivity of the method was sufficient to determine 
the concentration of ubiquinone in human plasma.  The peak of ubiquinone in plasma 
was clearly detected without interferences when the proposed method was applied to 
human plasma sample.  Therefore, the proposed method should be useful in a variety 
fields such as biological and pharmaceutical analyses.   
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Fig. 2.  Schematic diagram of the HPLC-CL system.  
Waste 












Fig. 3.   Chromatograms for (A) standard solution of 0.86 µg/mL ubiquinone 
and 0.45 µg/mL IS and (B) human plasma containing 0.40 µg/mL 
ubiquinone and 0.45 µg/mL IS obtained with the proposed CL 
detection and (C) human plasma containing 0.40 µg/mL ubiquinone 















































































Coil length, m 
Fig. 4.   Effects of reaction coil length on peak height and S/N ratio.   The 
concentrations of ubiquinone, DTT, luminol and NaOH are 0.43 µg/mL, 
1.5 mM, 1.0 mM and 150 mM, respectively. 





































Fig. 5.   Effects of luminol concentration on peak height and S/N ratio.   The concentrations 
of ubiquinone, DTT and NaOH are 0.43 µg/mL, 1.5 mM and 150 mM, respectively. 
The reaction coil length is 15 m. 




Table 1 Recovery of ubiquinone from spiked plasma samples 
Within-day (n=5) 
 Spiked concentration (µg/mL) Found ± SD  (µg/mL) RSD 
(%)
Recovery (%)
 0 0.40 ± 0.02 4.5 -
 0.43 0.84 ± 0.02 2.2 101
 1.73 2.10 ± 0.06 2.7 98
 8.63 9.07 ± 0.08 0.8 100
Between-day (n=5) 
 Spiked concentration (µg/mL) Found ± SD  (µg/mL) RSD 
(%)
Recovery (%)
 0.43 0.85 ± 0.03 3.4 103
 1.73 2.10 ± 0.06 2.7 99





Table 2 The stability of ubiquinone in human plasma samples 
 
 Accuracy (%) (mean ± SD, n = 3) 
Spiked concentration (µg/mL) 
0.43 1.73 8.63 
Room temperature for 4 h 90.5 ± 8.6 94.9 ± 4.1 95.5 ± 6.5 
Freezer at -80 °C for 2 weeks 92.1 ± 7.3 93.0 ± 8.4 93.2 ± 4.8 
Three-times freeze–thaw (-80 °C)  93.8 ± 3.1 94.8 ± 4.7 96.6 ± 6.5 
 
 
